WO2012170607A3 - Utilisation d'antagonistes de pcsk9 - Google Patents

Utilisation d'antagonistes de pcsk9 Download PDF

Info

Publication number
WO2012170607A3
WO2012170607A3 PCT/US2012/041214 US2012041214W WO2012170607A3 WO 2012170607 A3 WO2012170607 A3 WO 2012170607A3 US 2012041214 W US2012041214 W US 2012041214W WO 2012170607 A3 WO2012170607 A3 WO 2012170607A3
Authority
WO
WIPO (PCT)
Prior art keywords
pcsk9
pcsk9 antagonists
antagonists
apheresis
provides
Prior art date
Application number
PCT/US2012/041214
Other languages
English (en)
Other versions
WO2012170607A2 (fr
Inventor
William P. Dole
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of WO2012170607A2 publication Critical patent/WO2012170607A2/fr
Publication of WO2012170607A3 publication Critical patent/WO2012170607A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne l'utilisation thérapeutique chez des patients qualifiés pour une aphérèse d'antagonistes anticorps contre la proprotéine convertase subtilisine/kexine de type 9a (« PCSK9 »).
PCT/US2012/041214 2011-06-10 2012-06-07 Utilisation d'antagonistes de pcsk9 WO2012170607A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161495531P 2011-06-10 2011-06-10
US61/495,531 2011-06-10

Publications (2)

Publication Number Publication Date
WO2012170607A2 WO2012170607A2 (fr) 2012-12-13
WO2012170607A3 true WO2012170607A3 (fr) 2013-01-03

Family

ID=46298696

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/041214 WO2012170607A2 (fr) 2011-06-10 2012-06-07 Utilisation d'antagonistes de pcsk9

Country Status (1)

Country Link
WO (1) WO2012170607A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US8871913B2 (en) 2007-08-23 2014-10-28 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8999341B1 (en) 2014-07-15 2015-04-07 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9266961B2 (en) 2012-06-15 2016-02-23 Genentech, Inc. Anti-PCSK9 antibodies, formulations, dosing, and methods of use
US9439963B2 (en) 2014-07-15 2016-09-13 Kymab Limited Methods of treating anaemia

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171339A1 (en) * 2001-12-28 2005-08-04 Izumi Sugo Method of stabilizing protein
AU2011308496A1 (en) 2010-10-01 2013-05-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP4074834A1 (fr) 2012-11-26 2022-10-19 ModernaTX, Inc. Arn à terminaison modifiée
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
GB2523527A (en) * 2013-04-05 2015-09-02 Weiming Xu Screen compounds for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9)
WO2015017791A1 (fr) * 2013-08-01 2015-02-05 Atherotech, Inc. Analyse de la fonction de pcsk9
EP3052106A4 (fr) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
EP3052521A1 (fr) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucléotides codant pour un récepteur de lipoprotéines de faible densité
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
JP7032662B2 (ja) 2015-12-31 2022-03-09 ジエンス ヘンルイ メデイシンカンパニー リミテッド Ｐｃｓｋ９抗体、その抗原結合フラグメント及び医薬用途
EP3401336A4 (fr) 2016-01-05 2020-01-22 Jiangsu Hengrui Medicine Co., Ltd. Anticorps anti-pcsk9, fragment de liaison à l'antigène associé et application médicale associée
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018189705A1 (fr) 2017-04-13 2018-10-18 Cadila Healthcare Limited Vaccin pcsk9 à base de nouveaux peptides
WO2018232357A1 (fr) 2017-06-15 2018-12-20 Modernatx, Inc. Formulations d'arn
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
JP2022501367A (ja) 2018-09-20 2022-01-06 モデルナティエックス インコーポレイテッドModernaTX, Inc. 脂質ナノ粒子の調製及びその投与方法
EP3911648A4 (fr) 2019-01-18 2022-10-26 Astrazeneca AB Inhibiteurs de pcsk9 et leurs procédés d'utilisation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057459A2 (fr) * 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
WO2009026558A1 (fr) * 2007-08-23 2009-02-26 Amgen Inc. Protéines de liaison à un antigène pour proprotéine convertase subtilisine kexine de type 9 (pcsk9)
WO2009100297A1 (fr) * 2008-02-07 2009-08-13 Merck & Co., Inc. Antagonistes de pcsk9 1d05
WO2010068526A1 (fr) * 2008-12-12 2010-06-17 Merck Sharp & Dohme Corp. Immunodosage de pcsk9
WO2011072263A1 (fr) * 2009-12-11 2011-06-16 Irm Llc Antagonistes de pcsk9

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US7981843B2 (en) 2004-01-20 2011-07-19 Kalobios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
AU2005306502B2 (en) 2004-11-16 2012-11-15 Humanigen, Inc. Immunoglobulin variable region cassette exchange
US8211648B2 (en) 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057459A2 (fr) * 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
WO2009026558A1 (fr) * 2007-08-23 2009-02-26 Amgen Inc. Protéines de liaison à un antigène pour proprotéine convertase subtilisine kexine de type 9 (pcsk9)
WO2009100297A1 (fr) * 2008-02-07 2009-08-13 Merck & Co., Inc. Antagonistes de pcsk9 1d05
WO2010068526A1 (fr) * 2008-12-12 2010-06-17 Merck Sharp & Dohme Corp. Immunodosage de pcsk9
WO2011072263A1 (fr) * 2009-12-11 2011-06-16 Irm Llc Antagonistes de pcsk9

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LI HAI ET AL: "Recent patents on PCSK9: a new target for treating hypercholesterolemia", RECENT PATENTS ON DNA & GENE SEQUENCES,, vol. 3, no. 3, 1 November 2009 (2009-11-01), pages 201 - 212, XP002619049, ISSN: 1872-2156, DOI: 10.2174/187221509789318388 *
NI YAN G ET AL: "A PCSK9 C-terminal Domain Binding Fab Inhibits PCSK9 Internalization and Restores LDL-uptake", CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 120, no. 18, Suppl. 2, 1 November 2009 (2009-11-01), pages S477, XP008121212, ISSN: 0009-7322 *
NI YAN G ET AL: "A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, BETHESDA, MD, USA, vol. 285, no. 17, 23 April 2010 (2010-04-23), pages 12882 - 12891, XP002619048, ISSN: 1083-351X, [retrieved on 20100219], DOI: 10.1074/JBC.M110.113035 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871913B2 (en) 2007-08-23 2014-10-28 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9266961B2 (en) 2012-06-15 2016-02-23 Genentech, Inc. Anti-PCSK9 antibodies, formulations, dosing, and methods of use
US8999341B1 (en) 2014-07-15 2015-04-07 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9034331B1 (en) 2014-07-15 2015-05-19 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9439963B2 (en) 2014-07-15 2016-09-13 Kymab Limited Methods of treating anaemia

Also Published As

Publication number Publication date
WO2012170607A2 (fr) 2012-12-13

Similar Documents

Publication Publication Date Title
WO2012170607A3 (fr) Utilisation d'antagonistes de pcsk9
TN2012000243A1 (en) Pcsk9 antagonists
EP4252857A3 (fr) Procédés pour réduire les niveaux de lipoprotéine(a) par l'administration d'un inhibiteur de la proprotéine convertase subtilisine kexine 9 (pcsk9)
ZA201409210B (en) Methods and uses for proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors
HK1243075A1 (zh) 使前蛋白轉化酶枯草溶菌素/ kexin 9型(pcsk9)減少的方法
MY168961A (en) Antibodies to pcsk9 and uses thereof
MX2020010470A (es) Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9.
WO2014197752A8 (fr) Méthodes d'inhibition de l'athérosclérose consistant à administrer un inhibiteur de la pcsk9
EA201391157A1 (ru) Антагонисты pcsk9
MX2019006284A (es) Oligomeros antisentido y conjugados con diana en la proteina-convertasa subtilisina/kexina tipo 9(pcsk9).
MX2016006226A (es) Regimenes de dosificacion para uso con inhibidores de pcsk9.
NZ719345A (en) Lipid nanoparticle compositions and methods for mrna delivery
HK1202804A1 (en) Treatment with anti-pcsk9 antibodies pcsk9
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
WO2012173846A3 (fr) Macrocycles peptidomimétiques
EP2069377A4 (fr) Procédés et compositions pour le traitement de maladies et de troubles de la peau
EP3182971A4 (fr) Composition et procédés d'utilisation de petites molécules en tant que ligands de liaison pour la modulation de l'activité proprotéine convertase subtilisine/protéine kexine de type 9 (pcsk9)
WO2014033158A3 (fr) Vaccin
WO2013138338A3 (fr) Méthodes de traitement de lésions tissulaires, associées à l'ischémie, faisant appel à l'apolipoprotéine d
WO2012166991A8 (fr) S-nitrosylation de toxines de glucosylation et leurs utilisations
CA145238S (en) Cup for tea
NZ745686A (en) Lipid nanoparticle compositions and methods for mrna delivery

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12727735

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12727735

Country of ref document: EP

Kind code of ref document: A2